山西證券(002500.SZ):擬公開發行不超15億元公司債券
格隆匯11月15日丨山西證券(002500.SZ)公佈公司2021年面向專業投資者公開發行公司債券(第二期)發行公吿,本期債券的發行規模不超過15億元(含15億元),每張面值為人民幣100元,共計不超過1500萬張(含1500萬張),發行價格為100元/張。
本期債券簡稱為“21山證02”、債券代碼為“149708”。本期債券的票面利率詢價區間2.90%-3.70%。本期債券最終票面利率由發行人和主承銷商根據網下利率詢價情況在詢價區間範圍內協商確定。
發行人和主承銷商將於2021年11月17日(T-1日)以簿記建檔的方式向網下專業投資者進行利率詢價。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.